145 related articles for article (PubMed ID: 9712485)
1. The cytokine modulation of acute graft-versus-host disease.
Ferrara JL
Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S13-5. PubMed ID: 9712485
[TBL] [Abstract][Full Text] [Related]
2. The role of cytokines in acute graft-versus-host disease.
Hill GR; Krenger W; Ferrara JL
Cytokines Cell Mol Ther; 1997 Dec; 3(4):257-66. PubMed ID: 9740354
[TBL] [Abstract][Full Text] [Related]
3. The role of cytokines in graft-versus-host reactions and disease.
Jadus MR; Wepsic HT
Bone Marrow Transplant; 1992 Jul; 10(1):1-14. PubMed ID: 1515873
[TBL] [Abstract][Full Text] [Related]
4. Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Duran-Struuck R; Reddy P
Transplantation; 2008 Feb; 85(3):303-8. PubMed ID: 18301323
[TBL] [Abstract][Full Text] [Related]
5. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
7. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease.
Cooke KR; Olkiewicz K; Erickson N; Ferrara JL
J Endotoxin Res; 2002; 8(6):441-8. PubMed ID: 12697087
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation.
Nagler A; Bishara A; Brautbar C; Barak V
Cytokines Cell Mol Ther; 1998 Sep; 4(3):161-7. PubMed ID: 9825841
[TBL] [Abstract][Full Text] [Related]
10. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH
Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology of acute graft-versus-host disease.
Reddy P
Hematol Oncol; 2003 Dec; 21(4):149-61. PubMed ID: 14735553
[TBL] [Abstract][Full Text] [Related]
13. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
14. The effect of extracorporeal photopheresis on intracellular cytokine expression in chronic cutaneous graft-versus-host disease.
Darvay A; Salooja N; Russell-Jones R
J Eur Acad Dermatol Venereol; 2004 May; 18(3):279-84. PubMed ID: 15096136
[TBL] [Abstract][Full Text] [Related]
15. Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
Hess AD
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597
[TBL] [Abstract][Full Text] [Related]
16. The pathophysiology of acute graft-versus-host disease.
Jaksch M; Mattsson J
Scand J Immunol; 2005 May; 61(5):398-409. PubMed ID: 15882431
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
18. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
19. Alloreactive CD4 T lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RChigh but not the CD45RClow subset.
Xystrakis E; Bernard I; Dejean AS; Alsaati T; Druet P; Saoudi A
Eur J Immunol; 2004 Feb; 34(2):408-17. PubMed ID: 14768045
[TBL] [Abstract][Full Text] [Related]
20. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
